Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: Exas | History Defined

Texas Woman Says This Is The Best Car She's Ever Had. So Why Is The Dealership Taking It Away From Her?

"The best car that I've ever had, and I'm getting it taken away from me."

Motor1

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

Barchart

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

'Premeditated and Corny': LeBron James Calls Out Texas Cop in Viral Confrontation With South Carolina's Nyck Harbor

A video of a Texas trooper aggressively confronting South Carolina player Nyck Harbor during a college football game went viral and drew widespread criticism, including from LeBron James.

International Business Times UK

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

Benzinga

The Saturday Spread: Leveraging Practical Math to Extract Alpha in Hidden Places

In a world where generative AI is running amok, we can use empirical axioms to tilt the odds in our favor.

Barchart

1 'Strong Buy' Healthcare Stock to Scoop Up After Its Latest FDA Win

This top-rated healthcare stock is poised for substantial growth after securing FDA approval for its innovative non-invasive cancer diagnostic.

Barchart

Read news from The Economist, FT, and more,
with one subscription

1 Cathie Wood Stock with 65% Upside Potential

This stock holds a spot in maverick investor Wood's flagship fund, and analysts agree the cutting-edge diagnostics specialist has plenty of growth potential from current levels.

Barchart

3 Cathie Wood Stocks Beating the Nasdaq This Year

The maverick fund manager catches a lot of heat for her stock picks, but these three ARKK standouts are absolutely crushing the broader Nasdaq Composite so far in 2023.

Barchart

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Benzinga

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%. Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Benzinga

Analyst Ratings for Exact Sciences

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Benzinga

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.

StockNews.com

5 Cathie Wood Stocks Wall Street Predicts Will Rally 76% to 99%

Renowned institutional investor Cathie Wood of Ark Investments fame is known for her market-beating investment strategies. Ark’s portfolio companies are attractive investments due to their long-term high growth potential and ability to withstand the current industry headwinds. Thus, Wall Street analysts expect fundamentally solid Cathie Wood stocks Coinbase (COIN), Zoom…

Benzinga

Where Exact Sciences Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increas

StockNews.com

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

The healthcare industry is growing rapidly on increasing demand and continuing advancements in therapies. Furthermore, this year is expected to be a transformative one for the healthcare sector, with a more robust transition to digital health. Given the industry's growth potential, Wall Street analysts see more than 40% potential upside…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.